宫颈癌筛查采用Cervista与HC2法比较的研究进展

宫颈癌在女性生殖系统恶性肿瘤中发病率最高,且近年来其发病率和死亡率有明显增长趋势,尤其是在中青年女性中.全世界浸润性宫颈癌的HPV检出率99.3％,而部分HPV感染可以随着免疫力的增强逐渐被机体所清除;且早期病变演变为宫颈癌其潜伏期长达10年左右;再者,局部治疗即可阻止其进一步发生恶变,所以,通过筛查不但可早期发现宫颈的癌前病变,而且可早治疗、提高疗效、挽救生命.最新的Cervista酶切免疫放大技术特异性更高、假阳性更少,检测效率高、不确定率更低,本文通过与HC2对比,对该方法予以综述.

Difference of Cervista and HC2 in Cervical Cancer Screening

The incidence of Cervical Cancer is the supreme in female Genital system Malignant Cancer, and its morbidity and mortality have obvious rising tendency for the past few years, above all young and middle - aged femininity. The HPV relevance ratio of Invasive Carcinoma of Cervix Uteri in the World is 99. 3 percent, and some HPV infection could be enhanced gradually with the immunity was cleared by the body. Evolution of cervical cancer and early lesions need time is longer, usually 10 years. Moreover, local treatment can prevent the further enough, that, not only can through screening in the early detection of cervical precancerous lesions, and early Treatment to improve curative effect to save lives. The latest Cervista enzyme immune amplification technology specificity less higher false positive, high detection efficiency under uncertainty. In this paper, compared with HC2, for the method to be reviewed.